Viridian Therapeutics is a biotech company that develops treatments for serious and rare diseases. Their product pipeline includes monoclonal antibodies targeting insulin-like growth factor-1 receptor for the treatment of thyroid eye disease, as well as programs for rare and autoimmune diseases. The company is headquartered in Waltham, Massachusetts.